VolitionRx (NYSE-A:VNRX) Limited has announced that it is participating in a webinar hosted by Edison Group, to expound new cancer data to be presented on October 21 at ESMO 2023, the annual congress of the European Society for Medical Oncology.
The multi-national epigenetics company said the webinar will take place on Thursday, October 26 at 10:30 AM EDT and will include updates from Volition's chief scientific officer Dr. Jake Micallef, its chief commercial officer Gael Forterre, as well as Dr. Andrew Retter, a leading UK-based haematologist and medical consultant at Volition.
"Our upcoming webinar is a timely opportunity to talk through exciting breakthrough data in our Capture pillar, regarding what we believe to be an entirely new method for the early detection of cancer," Micallef said in a statement.
"We will provide stakeholders with deeper insights into the data we are presenting at ESMO 2023, and outline our next steps towards commercialization," he added.
The panel and Q&A event is being hosted by Soo Romanoff, managing director of healthcare at Edison Group.
To register for Volition's data insights webinar click HERE.
The event will be recorded and available afterward on demand.
VolitionRx (NYSE-A:VNRX) is a multi-national epigenetics company powered by Nu.Q, its proprietary nucleosome quantification platform.
Through its subsidiaries, Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19.
Contact Sean at sean@proactiveinvestors.com